Budget Impact of a Comprehensive Nutrition-Focused Quality Improvement Program for Malnourished Hospitalized Patients
Suela Sulo, PhD, Josh Feldstein, BA, Jamie Partridge, PhD, MBA, Bjoern Schwander, MS, RN, Krishnan Sriram, MD, Wm. Thomas Summerfelt, PhD
Healthcare is becoming more complex across all disciplines, at all levels, and throughout the world. As a result, practicing medicine that emphasizes the value received from an intervention is increasingly essential to the long-term sustainability of the healthcare delivery model.
The Crucial Role of Nutrition Support Services for Hospitalized Patients
The value of drugs, whether individually or comparatively, and the definition of value itself, have emerged as acute concerns in oncology, where the cost of cancer care has evoked issues of financial toxicity. In the United States alone, the costs associated with cancer treatment have been forecast to increase 27% from their 2010 levels, to approximately $157.8 billion by 2020.
Payers’ Utilization of Value Frameworks Tools in Their Drug Coverage Decision-Making
Hyperkalemia, which is defined as an elevated serum potassium level (ie, >5.0 mEq/L), may be caused by a reduction in the renal excretion of potassium or an intracellular-to-extracellular shift in potassium that results from various acute clinical conditions. Although the kidney can adjust to a reduced number of nephrons and maintain normokalemia under steady-state conditions, it lacks the ability to respond to acute increases in potassium load and to adequately excrete potassium in patients with chronic kidney disease (CKD); the result in both cases is hyperkalemia.
Hyperkalemia in Chronic Diseases: A Serious Medical Condition in Need of Clinical Guidelines and New Treatment Options
Academic Detailing Has a Positive Effect on Prescribing and Decreasing Prescription Drug Costs: A Health Plan’s Perspective
Does a Free Office Visit Affect Primary Care–Seeking Behavior? A Study of New Exchange Health Plan Enrollees in Mississippi
Bettina M. Beech, DrPH, MPH, Tristan Cordier, MPH, Laura E. Happe, PharmD, MPH, Laura Trunk, MD, Gilbert S. Haugh, MS, Richard Kwong, MPH, Vipin Gopal, PhD, Roy A. Beveridge, MD
In recent years, several health plans in the Health Insurance Marketplace exchange were offering free doctors’ visits to their members, with the hope of identifying illnesses before they become more difficult or more expensive to treat.
Patients’ Choice for Site of Care Motivated by More Than Cost Alone
Comparing Healthcare Costs Associated with Oral and Subcutaneous Methotrexate or Biologic Therapy for Rheumatoid Arthritis in the United States
Joseph Lee, PhD, Ryan Pelkey, MS, Julieanna Gubitosa, BS, Michael F. Henrick, MBA, Michael L. Ganz, MS, PhD
Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults, with a prevalence of approximately 0.6% in the United States. RA has a significant negative impact on health-related quality of life and imposes a substantial economic burden on the US healthcare system.
Identifying the Most Clinically and Economically Effective Therapies for Rheumatoid Arthritis Remains a Challenge for Providers and Payers
Sociodemographic Determinants of Out-of-Pocket Expenditures for Patients Using Prescription Drugs for Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory disease that is typically accompanied by swelling, tenderness of the joints, and destruction of the synovial joints. The progression of RA can cause disability and can have serious physical, mental, and economic consequences for patients.
Understanding Patients’ Demographics Is Key to Improving Clinical and Economic Healthcare Outcomes
Biologic Disease-Modifying Antirheumatic Drugs in a National, Privately Insured Population: Utilization, Expenditures, and Price Trends
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease of unknown cause that primarily affects the peripheral joints in a symmetric pattern. RA’s effect on other areas of the body, including the skin, heart, lungs, and eyes, can be substantial.
Rheumatoid Arthritis, Biologic Drugs, and Associated Cost
Leveraging Real-World Evidence in Disease-Management Decision-Making with a Total Cost of Care Estimator
Thanh-Nghia Nguyen, DrPH, MPH, MBA, Jeffrey Trocio, MPH, Stacey Kowal, MS, Cheryl P. Ferrufino, Julie Munakata, MS, Dell South, PharmD
The healthcare system in the United States is evolving as a result of the increasing availability of real-world data and the influence of value-based policy and quality initiatives.
Hypothesis Generation: An Essential Component of Informed Healthcare Management
Use of the Prostate Core Mitomic Test in Repeated Biopsy Decision-Making: Real-World Assessment of Clinical Utility in a Multicenter Patient Population
Prostate cancer is the second most common invasive cancer diagnosed among men worldwide, and the most common cancer diagnosed in developed regions of the world, with an estimated age-standardized rate of 63 cases per 100,000 person-years.
Molecular Tests May Aid Clinical Decision-Making and Reduce Healthcare Costs
Page 1 of 11
Results 1 - 10 of 105
Results 1 - 10 of 105